Mode
Text Size
Log in / Sign up

MTHFR C677T polymorphism linked to elevated risk of schizophrenia and type 2 diabetes comorbidity in Han Chinese patientsGene variation linked to higher risk of schizophrenia and diabetes in Chinese patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider MTHFR C677T polymorphism as a potential genetic marker for schizophrenia and type 2 diabetes comorbidity in this population.

This observational cohort study was conducted at Liaocheng Fourth Peoples Hospital involving 120 Han Chinese participants. The population included patients with comorbid schizophrenia and type 2 diabetes mellitus compared against a healthy control group. The primary exposure assessed was the MTHFR C677T gene polymorphism and MTHFR promoter methylation status.

The analysis revealed that the MTHFR C677T polymorphism was significantly associated with an elevated risk of the comorbidity, with a p-value less than 0.05. In contrast, MTHFR promoter methylation levels were not significantly higher in the patient group compared to controls, with reported percentages of 95.00% for the patient group versus 90.00% for the control group (p>0.05).

No adverse events, discontinuations, or tolerability data were reported as this was an observational study assessing genetic markers rather than an intervention trial. The study notes that genetic variation in MTHFR, rather than promoter methylation, appears to contribute critically to the comorbidity. However, the lack of reported certainty notes and the observational nature of the design prevent definitive causal conclusions regarding the genetic markers and disease risk.

Key takeaway: Consider the MTHFR C677T polymorphism as a potential genetic marker for schizophrenia and type 2 diabetes comorbidity in this population.

A study from Liaocheng Fourth Peoples Hospital examined whether specific genetic changes were connected to having both schizophrenia and type 2 diabetes at the same time. The research team looked at 120 patients who had both conditions and compared them to a group of healthy people without these illnesses. They focused on two genetic markers related to the MTHFR gene, which plays a role in how the body processes certain nutrients.

The analysis revealed that one specific gene variation, known as the MTHFR C677T polymorphism, was significantly associated with an increased risk of developing this combination of disorders. In contrast, the study did not find a significant difference in another genetic marker called promoter methylation between the sick group and the healthy controls. The researchers noted that the gene variation appeared to contribute more critically to the shared risk than the methylation pattern did.

Because this was a small observational study, the results show a link but do not prove that the gene directly causes the diseases. The findings may not apply to people outside this specific Chinese population, and more research is needed to confirm these results in larger groups. Readers should understand that having this gene variation does not guarantee a person will develop these conditions, and it is not a diagnosis tool on its own.

What this means for you:
Small study links one gene variation to higher risk of having both schizophrenia and diabetes in Chinese patients.

Study Details

Sample sizen = 120
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Schizophrenia (SCZ) and type 2 diabetes mellitus (T2DM) are common comorbid disorders that severely impair patient prognosis and quality of life. This study aimed to explore the association between the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and MTHFR promoter methylation in patients with comorbid SCZ and T2DM. A total of 120 participants were enrolled from Liaocheng Fourth Peoples Hospital between January 2025 and June 2025, comprising 30 subjects in each of the four groups: SCZ group, T2DM group, SCZ-T2DM comorbid (SCZ+T2DM) group, and healthy control (CTL) group. Corresponding primers were designed for genetic analysis, and methylation-specific PCR (MSP) was performed to detect the methylation level of the MTHFR promoter. Genotype distribution of the MTHFR C677T polymorphism was consistent with Hardy-Weinberg equilibrium (HWE) (p>0.05). The C677T polymorphism was significantly associated with an elevated risk of SCZ and T2DM comorbidity (p<0.05). Notably, the methylation rate of the MTHFR promoter in the SCZ+T2DM group (95.00%) was not significantly higher than that in the CTL group (90.00%) (p>0.05). In conclusion, the MTHFR gene may serve as a susceptibility gene for SCZ-T2DM comorbidity, whereas MTHFR promoter methylation is not associated with the pathogenesis of this comorbid condition. These results indicate that genetic variation in MTHFR, rather than promoter methylation, contributes critically to the comorbidity of SCZ and T2DM in the Han Chinese population. Our findings may provide novel molecular insights into their shared pathophysiology and inform future clinical strategies for patients with this complex phenotype.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.